Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07006662

Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction

Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction — Recruiting • Oncology • NCT07006662.

📅 09 Sep 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07006662
Sponsor
University Hospitals of North Midlands NHS Trust
Start
2026-08-04
ClinicaliQ Trial Snapshot
  • Anatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction — Recruiting • Oncology • NCT07006662.
  • Sponsor: University Hospitals of North Midlands NHS Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The aim of this 6-month proof-of-concept study is to map out the chest wall perforators in relation to anatomical landmarks for partial breast reconstruction.

Eligibility Snapshot
  • : * Patients undergoing elective breast surgery * Age ≥ 18 years * Female * BMI ≤ 30 kg/m2 * Willing and able to give fully informed consent, * Willing and able to comply with the study procedures

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Lucy Davis urges women to check their breasts for cancer – here’s how
Oncology · BBC Health · 12 Aug 2026
Breast cancer can present as subtle findings—a hard spot rather than a discrete lump—emphasising the importance of thorough self-examination and patient awareness…
View brief →
Guideline
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)
Oncology · 18 Jun 2026
Imlunestrant evaluation was terminated – NICE did not complete appraisal of imlunestrant for oestrogen receptor-positive HER2-negative advanced breast cancer; clinicians should refer…
View guideline →
Clinical Brief
Heart trial after breast cancer has ‘improved my life’
Oncology · BBC Health · 02 Sep 2026
Women completing breast cancer treatment can safely discontinue cardioprotective medications (likely ACE inhibitors/beta-blockers) without adverse cardiac outcomes, based on evidence from a…
View brief →
Clinical Brief
Are current breast cancer checks good enough?
Oncology · BBC Health · 04 Aug 2026
Current breast cancer screening pathways fail to identify up to 95% of younger women at genuinely higher risk, suggesting substantial gaps in…
View brief →
Clinical Brief
Breast cancer checks missing most women under 50 who are at risk, says study
Oncology · BBC Health · 04 Aug 2026
Current NHS breast screening programmes fail to identify approximately 95% of women under 50 at higher genetic or familial risk of breast…
View brief →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →